Efficacy of omarigliptin, once-weekly dipeptidyl peptidase-4 inhibitor, in patients with type 2 diabetes

Table 1 Clinical characteristics of patients with type 2 diabetes who received omarigliptin divided according to add-on to or switched from daily dipeptidyl peptidase-4 inhibitor

	AO (n = 18)	L→Om (n = 6)	S→Om (n = 10)	V→Om (n = 15)
Male : Female	13 : 5	4 : 2	5 : 5	13 : 2
Age (yr)	66.8 ± 12.1	75.2 ± 9.0	63.6 ± 15.7	70.1 ± 8.7
Duration (yr)	12.0 ± 10.1	15.5 ± 10.7	11.2 ± 5.6	12.9 ± 4.8
BMI (kg/m2)	24.1 ± 3.3	24.9 ± 1.6	23.5 ± 2.4	23.7 ± 3.4
eGFR (mL/min/1.73 m2)	63.6 ± 19.5	45.0 ± 22.2a	76.1 ± 17.5	63.3 ± 15.7
HbA1c (%)	7.48 ± 1.28	6.33 ± 0.79	6.88 ± 0.37	7.14 ± 0.66
Metformin use	8 (44%)	1 (17%)	4 (40%)	6 (40%)
Insulin secretagogues1 use	5 (28%)	0 (0%)	4 (40%)	8 (53%)
Insulin use	2 (11%)	0 (0%)	1 (10%)	3 (20%)

¹Insulin secretagogues include sulfonylurea and glinide, but not dipeptidyl peptidase-4 inhibitor.

Data are shown as mean ± SD or n (%) unless otherwise indicated. AO: Add-on; BMI: Body mass index; eGFR: Estimated glomerular filtration rate; HbA1c: Hemoglobin A1c; L→Om: Switch from linagliptin to omarigliptin; S→Om: Switch from sitagliptin to omarigliptin; V→Om: Switch from vildagliptin to omarigliptin. ^aP < 0.05 vs S→Om group (multiple comparison).